Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 20/20 | 0.73 |
| ▸ | PPARA | Q07869 | 19/20 | 0.73 |
| ▸ | PPARD | Q03181 | 16/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5015834 | 0.90 | PPARG (0.86) | PPARGPPARAPPARD | |
| SCHEMBL5781088 | 0.89 | PPARG (0.74) | PPARGPPARAPPARD | |
| SCHEMBL5781999 | 0.87 | PPARG (0.75) | PPARGPPARAPPARD | |
| SCHEMBL5780629 | 0.86 | PPARG (0.76) | PPARGPPARAPPARD | |
| SCHEMBL5779874 | 0.85 | PPARG (0.74) | PPARGPPARAPPARD | |
| SCHEMBL5784097 | 0.85 | PPARG (1.00) | PPARGPPARAPPARD | |
| SCHEMBL5017607 | 0.84 | PPARG (0.75) | PPARGPPARAPPARD | |
| SCHEMBL5781796 | 0.83 | PPARG (0.88) | PPARGPPARAPPARD | |
| SCHEMBL5015733 | 0.82 | PPARG (1.00) | PPARGPPARAPPARD | |
| SCHEMBL5780682 | 0.82 | PPARG (0.80) | PPARGPPARAPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1539746-B1 | N-SUBSTITUTED-1H-INDOL-5-PROPIONIC ACID COMPOUNDS AS PPAR AGONISTS USEFUL FOR THE TREATMENT OF DIABETES | HOFFMANN LA ROCHE (CH) | 2006-11-15 | — | — | EP | claimed |
| EP-1539746-A1 | N-SUBSTITUTED-1H-INDOL-5-PROPIONIC ACID COMPOUNDS AS PPAR AGONISTS USEFUL FOR THE TREATMENT OF DIABETES | F. HOFFMANN-LA ROCHE AG (CH) | 2005-06-15 | — | — | EP | claimed |
| US-6890947-B2 | Indolyl derivatives | HOFFMANN-LA ROCHE INC. (US) | 2005-05-10 | — | — | US | claimed |
| WO-2004024726-A1 | N-SUBSTITUTED-1H-INDOL-5-PROPIONIC ACID COMPOUNDS AS PPAR AGONISTS USEFUL FOR THE TREATMENT OF DIABETES | F. HOFFMANN-LA ROCHE AG (CH) | 2004-03-25 | — | — | WO | claimed |
| US-20040053979-A1 | Indolyl derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2004-03-18 | — | — | US | claimed |
| EP-1539746-B1 | N-SUBSTITUTED-1H-INDOL-5-PROPIONIC ACID COMPOUNDS AS PPAR AGONISTS USEFUL FOR THE TREATMENT OF DIABETES | HOFFMANN LA ROCHE (CH) | 2006-11-15 | — | — | EP | disclosed |
| EP-1539746-A1 | N-SUBSTITUTED-1H-INDOL-5-PROPIONIC ACID COMPOUNDS AS PPAR AGONISTS USEFUL FOR THE TREATMENT OF DIABETES | F. HOFFMANN-LA ROCHE AG (CH) | 2005-06-15 | — | — | EP | disclosed |
| US-6890947-B2 | Indolyl derivatives | HOFFMANN-LA ROCHE INC. (US) | 2005-05-10 | — | — | US | disclosed |
| WO-2004024726-A1 | N-SUBSTITUTED-1H-INDOL-5-PROPIONIC ACID COMPOUNDS AS PPAR AGONISTS USEFUL FOR THE TREATMENT OF DIABETES | F. HOFFMANN-LA ROCHE AG (CH) | 2004-03-25 | — | — | WO | disclosed |
| US-20040053979-A1 | Indolyl derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2004-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040053979-A1 | Indolyl derivatives | UGT1A8, CYP2C8, UGT1A1 | PPARG 443/4885PPARA 617/4885PPARD 602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.